Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

14.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy in Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis: From Poor Prognosis to Curative-Intent Strategies.

Cancers·2026
Same author

A new effective treatment for dyslexia based on dorsal visual stream neuromodulation.

Journal of neurodevelopmental disorders·2026
Same author

Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study.

Alimentary pharmacology & therapeutics·2026
Same author

Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update.

Life (Basel, Switzerland)·2025
Same author

Bridging Gaps in Cancer Pain Care: Barriers, Solutions, and a Path Forward for Integrated Management.

Current oncology (Toronto, Ont.)·2025

Related Experiment Video

Updated: Feb 28, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

830

New Treatment Options for MASLD Patients with Type 2 Diabetes.

Andrea Mega1, , Chiara Turri1

  • 1Department of Gastroenterology, South-Tyrolean Healthcare System (SABES-ASDAA), Bolzano General Hospital, 39100 Bolzano, Italy.

Life (Basel, Switzerland)
|February 27, 2026
PubMed
Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) share links. Novel glucose-lowering drugs show promise in treating MASLD and T2DM complications, including liver fibrosis.

Keywords:
cirrhosisfibrosisglucagon-like peptide-1 agonistsmetabolic dysfunction-associated steatohepatitismetabolic dysfunction-associated steatotic liver diseaseoral glucose-lowering agentsodium-glucose co-transporter 2 inhibitorstransient elastographytype 2 diabetes

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

692
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.9K

Related Experiment Videos

Last Updated: Feb 28, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

830
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

692
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.9K

Area of Science:

  • Hepatology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by liver fat accumulation in individuals with cardiometabolic risk factors, frequently type 2 diabetes mellitus (T2DM).
  • MASLD encompasses a spectrum from simple steatosis to advanced fibrosis, cirrhosis, and hepatocellular carcinoma, with affected patients exhibiting an elevated risk of T2DM.
  • The co-occurrence of MASLD and T2DM is attributed to shared pathophysiological pathways, some of which are amenable to T2DM treatments.

Purpose of the Study:

  • To review the intricate relationship between MASLD and T2DM.
  • To examine current strategies for evaluating liver fibrosis in MASLD patients.
  • To assess the impact of emerging glucose-lowering therapies on MASLD and T2DM.

Main Methods:

  • Literature review focusing on the interplay between MASLD and T2DM.
  • Analysis of international guidelines for liver fibrosis risk stratification (FIB-4 index, transient elastography).
  • Evaluation of evidence for novel therapeutic agents, including GLP-1RAs and SGLT2is, in MASLD patients with T2DM.

Main Results:

  • GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is) demonstrate efficacy in improving metabolic parameters and liver steatosis/fibrosis in MASLD patients with T2DM.
  • GLP-1RAs enhance hepatic insulin signaling, regulate lipid metabolism, and reduce inflammation and oxidative stress.
  • Resmetirom is recommended for non-cirrhotic MASH with significant fibrosis, while GLP-1RAs are indicated for MASH and T2DM/obesity.

Conclusions:

  • The connection between MASLD and T2DM necessitates integrated management strategies.
  • Glucose-lowering drugs, particularly GLP-1RAs and SGLT2is, offer significant benefits for MASLD patients with T2DM.
  • Further research into fibrosis evaluation and targeted therapies is crucial for improving outcomes in this patient population.